VEGFA and ovarian carcinoma: Currently, targeted therapeutic agents that have been used in ovarian cancer include olaparib and niraparib, VEGF inhibitors, and the antiangiogenesis inhibitor bevacizumab, but the above-targeted agents are less used in clinical practice because of their narrow indications, high prices, and certain adverse effects [19–21].